How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.com
An Open-label, Phase I Study to Evaluate the Safety, Radiation Dosimetry and Pharmacokinetics of 89Zr-TLX250 PET/CT in Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma
Description:
The study is designed to evaluate the safety, tolerability, radiation dosimetry and pharmacokinetics 89Zr-TLX250 (also known as 89Zr-DFO-girentuximab) Positron Emission Tomography/Computed Tomography (PET/CT) in adult Chinese patients with indeterminate renal masses or Suspected Recurrent Renal Clear Cell Carcinoma
Sponsor:
Telix PharmaceuticalsPhase:
Phase 1
Contacts:
Principal Investigatorinfo@telixpharma.com
Government Study Link:
NCT05861778 - Click here to see study onClinicalTrials.gov
Isotope(s):
ZIRCONIUM-89
Radioisotope: Zr89
Theranostic Role: PET Imaging
T1/2 (Half-Life): 78 Hours
Decay Mode: POSITRON β+ (22%), ELECTRON CAPTURE (76%), GAMMA
Energy: max 0.9 MeV, E mean 397 keV, Gamma 511 keV
Range: N/A
Decay Daughters: Y89 (Stable)
Status: Clinical Trials Only
Target(s):
Inclusion
- Mainland Chinese, male or female, >=18 years old
- Scheduled for lesion resection as part of regular diagnostic workup within 90days from planned TLX250-CDx administration
- Imaging evidence of a single indeterminate renal mass of <=7cm on CT or MRI that is suspicious for ccRCC
Exclusion
- Renal mass known to be a metastasis of another primary tumor
- Planned antineoplastic therapies for the period between administration and imaging
- Chemo-, radio-, immuno-, or targeted therapy w/in 4w prior to planned administration
- Multiple unilateral or bilateral indeterminate renal masses
- A biopsy procedure only (rather than partial or total nephrectomy) planned for histological species delineation of mass
Patient Education
Patient Education Not Yet Provided
Locations
Loading...
Share your feedback
Help us improve your experience